NASDAQ: ABVC - ABVC BioPharma, Inc.

Rentabilidad a seis meses: -3.24%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción ABVC BioPharma, Inc.


Acerca de la empresa ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

más detalles
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

IPO date 2017-10-11
ISIN US00091F1066
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.abvcpharma.com
Цена ао 0.688
Cambio de precio por día: +0.0155% (0.6459)
Cambio de precio por semana.: +2.15% (0.6324)
Cambio de precio por mes: +54.18% (0.419)
Cambio de precio en 3 meses.: +26.67% (0.51)
Cambio de precio en seis meses: -3.24% (0.6676)
Cambio de precio por año: -44.31% (1.16)
Cambio de precio en 3 años.: -71.67% (2.28)
Cambio de precio en 5 años.: -89.58% (6.2)
Cambio de precio en 10 años.: +0% (0.646)
Cambio de precio desde principios de año.: +9.36% (0.5907)

Subestimación

Nombre Significado Calificación
P/S 34.42 1
P/BV 0.6113 10
P/E 0 0
EV/EBITDA -0.8525 0
Total: 4.25

Eficiencia

Nombre Significado Calificación
ROA, % -70.37 0
ROE, % -118.96 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.2994 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % -78.29 0
Rentabilidad Ebitda, % 146.44 10
Rentabilidad EPS, % 7.8 1
Total: 5.2



Supervisor Título profesional Pago año de nacimiento
Mr. Eugene Jiang Chairman & Chief Business Officer 200k 1986 (39 años)
Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer & Director 200k 1954 (71 año)
Dr. Uttam Yashwant Patil Ph.D. CEO & Interim CFO N/A 1986 (39 años)

DIRECCIÓN: United States, Fremont. CA, 44370 Old Warm Springs Boulevard - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.abvcpharma.com